SleepUp
Digital Therapeutics IoT platform for personalized and clinically validated treatment, monitoring, and diagnostics for sleep disorders.
Website: https://en.sleepup.com.br/
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Company | SleepUp |
| Tagline | Digital Therapeutics IoT platform for personalized and clinically validated treatment, monitoring, and diagnostics for sleep disorders. |
| Headquarters | São Caetano do Sul, Brazil |
| Founded | 2019 |
| Stage | Seed |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Latin America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed (total disclosed ~$2.1M) |
Links
PUBLIC
- Website: https://en.sleepup.com.br
- LinkedIn: https://www.linkedin.com/company/sleepup/
- Google Play: https://play.google.com/store/apps/details?id=com.sleepup.app
Executive Summary
PUBLIC SleepUp is a Brazilian digital therapeutics platform that has secured first-mover regulatory approval in its home market, a wedge that merits investor attention for its potential to scale a clinically validated sleep treatment across Latin America. Founded in 2019 by Renata Redondo Bonaldi and Bruno Montez-Carpes, the company developed its software-as-a-medical-device application after identifying a gap in accessible, non-pharmacological sleep disorder care [Digital Therapeutics Alliance]. The core product combines a Cognitive Behavioral Therapy for Insomnia (CBTi) program, registered with Brazil's ANVISA as a Class II medical device, with a proprietary wearable EEG headband and AI-driven personalization, moving beyond simple sleep tracking into integrated therapeutic intervention [Perplexity Sonar Pro Brief]. The founding team brings complementary operational and financial leadership, with CEO Renata Redondo Bonaldi actively shaping public discourse on digital health in Brazil [Health Podcast Network]. The company has raised an estimated $2.1 million across several seed rounds from regional investors including Criatec 4 and Sororité, deploying a B2B2C model that currently routes through retail pharmacy chains and corporate health plans in Brazil [Pequenas Empresas Grandes Negócios, Jul 2025]. Over the next 12-18 months, the key monitors will be the commercial traction of this pharmacy distribution partnership, any expansion of its ANVISA approval to adjacent neurological indications, and the translation of its regulatory lead in Brazil into concrete partnerships in other regulated Latam markets.
Data Accuracy: YELLOW -- Core product and regulatory status are well-documented by industry and government sources; funding total is an aggregate estimate from third-party platforms.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Latin America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | ~$2,055,500 (estimated) |
Company Overview
PUBLIC
SleepUp was founded in 2019 in São Paulo, Brazil, as a response to the significant gap in accessible, clinically validated treatments for sleep disorders [Crunchbase]. The company operates primarily through its Brazilian legal entity, SLEEPUP TECNOLOGIA EM SAUDE LTDA, headquartered in São Caetano do Sul, and maintains a UK entity, SLEEPUP LIMITED, registered in London [Perplexity Sonar Pro Brief]. Its early trajectory was marked by participation in accelerator programs, including the Founder Institute, Samsung, and Albert Einstein accelerators, which provided initial validation and structure.
A key operational milestone was the July 2020 launch of its core mobile application, which had accumulated over 8,000 users by November 2021 [Pequenas Empresas Grandes Negócios, Nov 2021]. The company achieved a critical regulatory breakthrough by becoming the first digital therapeutic (DTx) approved by ANVISA, Brazil's health regulatory agency, for the treatment of sleep disorders [Digital Therapeutics Alliance]. This approval, classifying its CBTi-based software as a Class II medical device, established a significant first-mover advantage in the domestic market.
Financially, SleepUp has raised an estimated $2.1 million across several seed rounds between 2021 and 2025 from a consortium of Brazilian investors, including Sororité and Criatec 4 [Canaltech, Nov 2021] [Pequenas Empresas Grandes Negócios, Jul 2025]. The company's commercial strategy evolved into a B2B2C model, with the Digital Therapeutics Alliance noting its operation within retail pharmacy chains and health companies in Brazil [Digital Therapeutics Alliance].
Data Accuracy: YELLOW -- Foundational details (founding year, HQ, regulatory status) are confirmed by multiple sources, but some milestone dates and specific funding round details rely on single-source reports.
Product and Technology
MIXED
SleepUp’s product is a clinically integrated system, not a simple tracking app. The core is a software-as-a-medical-device application delivering Cognitive Behavioral Therapy for Insomnia (CBTi), which is registered with Brazil’s ANVISA as a Class II medical device for treating insomnia and subjective sleep complaints in adults [Digital Therapeutics Alliance]. This regulatory approval, cited as a first for a digital therapeutic in Brazil for sleep disorders, forms the foundation of its market position [Digital Therapeutics Alliance].
The platform extends beyond software into hardware and data science. It incorporates a proprietary wearable EEG headband for monitoring brain activity, alongside a separate sleep screening oximeter, moving the product from passive tracking into active diagnostic and therapeutic territory [SleepUp App - App Store, 2026]. The company describes using machine learning algorithms on EEG and other biomarker data to generate personalized recommendations, though the specific models and training datasets are not detailed in public materials [Perplexity Sonar Pro Brief]. The complete solution integrates a cloud platform, mobile apps for Android and iOS, a web portal, and features for remote consultation via chat or video within a secure environment [Perplexity Sonar Pro Brief].
Data Accuracy: YELLOW -- Core product and regulatory claims are well-sourced; technical implementation details are less directly verified.
Market Research
PUBLIC
The market for technology-enabled sleep solutions is expanding beyond consumer wearables into clinically validated therapeutics, a shift driven by rising global sleep disorder prevalence and increasing payer recognition of digital interventions.
Third-party market sizing data points to a substantial and growing addressable market for sleep technology. The global market for sleep tech devices, a broad category that includes diagnostic and therapeutic hardware, was valued at $21.1 billion in 2023, up from $17.9 billion the prior year [gminsights.com, 2026]. While this figure encompasses a wide range of products, it provides a relevant analog for the hardware-enabled segment SleepUp operates within. More specific to therapeutic interventions, the global market for sleeping pods, a niche but adjacent category focused on rest environments, was valued at approximately $2.46 billion in 2025 and is projected to grow at a compound annual rate of 10.5% through 2035 [businessresearchinsights.com, 2026]. These figures suggest sustained investor and consumer interest in solutions addressing sleep quality.
Demand is anchored by a high and growing burden of sleep disorders, with insomnia being the most common. The core driver for a digital therapeutic like SleepUp is the significant treatment gap; traditional options like pharmacotherapy or in-person cognitive behavioral therapy are often inaccessible, stigmatized, or carry side effects. This creates a tailwind for scalable, software-delivered interventions. Furthermore, the gradual integration of digital therapeutics into formal healthcare pathways, evidenced by regulatory approvals and health technology assessments, is a critical enabling force. SleepUp's ANVISA clearance in Brazil and its evaluation by the Abu Dhabi Department of Health are early indicators of this trend moving into practice [Digital Therapeutics Alliance], [Abu Dhabi Department of Health].
SleepUp's solution sits at the intersection of several adjacent markets: consumer sleep tracking apps, medical-grade diagnostic devices, and traditional behavioral health services. Key substitutes include over-the-counter sleep aids, prescription medications, and direct-to-consumer meditation apps. The company's regulatory status as a Class II medical device aims to differentiate it from wellness apps by claiming a therapeutic effect, which is necessary for reimbursement discussions with health plans and institutional buyers. Macro forces, including increased remote care adoption and a focus on preventive health, further support the model.
Sleep Tech Devices 2022 | 17.9 | $B
Sleep Tech Devices 2023 | 21.1 | $B
Sleeping Pod Market 2025 | 2.46 | $B
Sleeping Pod Market 2026 | 2.72 | $B
The available market data, while not specific to digital therapeutics for insomnia, illustrates consistent growth in the broader sleep technology sector. The ~18% year-over-year increase in the sleep tech devices market from 2022 to 2023 indicates strong underlying momentum. The sleeping pod market's projected steady growth further confirms capital allocation toward sleep-focused innovations.
Data Accuracy: GREEN -- Market sizing figures are from published third-party industry reports.
Competitive Landscape
MIXED SleepUp's primary competitive advantage is not technological superiority over global giants, but a first-mover regulatory foothold in a specific, high-barrier geography.
No named competitors were identified in the captured sources, making a direct comparison table unfeasible. The analysis therefore proceeds by mapping the broader landscape of alternatives available to a Brazilian consumer or healthcare institution seeking sleep disorder solutions.
The competitive map can be segmented into three tiers. First, incumbent medical device and pharmaceutical companies like Philips (with its DreamStation sleep therapy devices) and a range of prescription sleep aids represent the traditional standard of care. These are deeply entrenched in the healthcare reimbursement system but offer limited personalization and no integrated digital therapeutic component. Second, global digital health and wellness apps such as Calm, Headspace, and even Apple's sleep tracking features provide accessible, low-cost mindfulness and basic sleep hygiene tools. However, they lack clinical validation as medical devices and cannot diagnose or treat specific sleep disorders like insomnia. Third, and most directly relevant, are other digital therapeutics (DTx) and sleep tech platforms. While no direct Brazilian competitor was cited, global peers like Big Health (Sleepio) and Pear Therapeutics (which had a CBTi product prior to its bankruptcy) illustrate the model. SleepUp's edge here is its ANVISA Class II approval, a status that likely remains unique in Brazil for a sleep-focused DTx [Digital Therapeutics Alliance].
SleepUp's defensible edge today rests on two pillars: regulatory status and integrated hardware. Being the first ANVISA-approved DTx for sleep disorders creates a significant moat, as replicating this approval requires time, clinical trials, and local regulatory expertise. The proprietary EEG headband also differentiates it from software-only CBTi apps, allowing for biomarker-based personalization. The durability of this edge is mixed. The regulatory advantage is perishable; another company could eventually secure similar approval. The hardware-software integration is more durable, protected by the development time and proprietary data it generates, but could be challenged by partnerships between existing wearable makers (e.g., Fitbit, Withings) and therapeutic software providers.
The company's most significant exposure lies in its limited scale and brand recognition compared to well-funded global wellness platforms, and its reliance on a B2B2C distribution model through unnamed pharmacy and health company partners. A specific risk is that a large incumbent like a pharmaceutical retailer or health insurer could develop or white-label a competing digital therapeutic, leveraging their existing customer relationships to bypass SleepUp's channel partnerships. Furthermore, the company has not demonstrated an ability to compete outside the Portuguese-speaking Brazilian market, leaving it vulnerable to international players should they decide to pursue ANVISA approval.
The most plausible 18-month scenario sees SleepUp consolidating its position as the leading sleep DTx in Brazil by deepening partnerships with major pharmacy chains and securing its first enterprise contract with a national health plan. The "winner" in this scenario is SleepUp, if it can convert its regulatory lead into exclusive, long-term distribution agreements before competitors enter. The "loser" would be generic sleep tracking apps attempting to gain medical credibility in Brazil, as they would face the same regulatory hurdles without SleepUp's head start. The critical variable is whether SleepUp can use this window to build a sufficiently large and engaged user base that creates network effects and proprietary data advantages, making its position defensible even after competitors eventually achieve regulatory clearance.
Data Accuracy: YELLOW -- Competitive analysis is inferred from market segments as no direct competitors were named in captured sources. SleepUp's regulatory status is confirmed by the Digital Therapeutics Alliance.
Opportunity
PUBLIC
If SleepUp can convert its first-mover regulatory status in Brazil into a dominant clinical pathway for sleep disorders, it could build a foundational digital health platform for a population of over 200 million people.
The headline opportunity is to become the default clinical-grade sleep management system for the Brazilian healthcare system. The company is not just another wellness app; it is the first digital therapeutic approved by ANVISA for sleep disorders in the country [Digital Therapeutics Alliance]. This regulatory clearance creates a tangible wedge into institutional sales channels, specifically retail pharmacy chains and health companies, which are already cited as its operating venues [Digital Therapeutics Alliance]. The path from a niche DTx to a systemic standard is plausible because it addresses a clear, high-prevalence clinical need with a scalable software solution, a combination that large payers and providers are increasingly seeking to manage costs and outcomes. Becoming the embedded, reimbursable sleep therapy within major health plans or public health initiatives represents a multi-billion Real revenue opportunity.
Growth is not monolithic and could follow several distinct, concrete paths. The following scenarios outline specific routes to scale, each grounded in the company's existing assets.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| B2B2C Pharmacy Dominance | SleepUp becomes the prescribed digital therapy dispensed at major Brazilian pharmacy chains for mild-to-moderate insomnia. | A national partnership with a top-3 pharmacy retailer (e.g., RaiaDrogasil, Panvel) to integrate SleepUp into their clinical services. | The company is already operating in retail pharmacy chains [Digital Therapeutics Alliance], establishing the initial commercial footprint needed for a scaled rollout. |
| Corporate Wellness Mandate | Large employers and health plans in Brazil adopt SleepUp as a covered benefit to reduce absenteeism and healthcare costs linked to poor sleep. | A landmark study published with a major Brazilian university or insurer demonstrating SleepUp's ROI in a corporate cohort. | The platform's ANVISA approval provides the clinical validation required for corporate health budgets, moving it beyond a discretionary wellness perk. |
| International Regulatory Replication | SleepUp's ANVISA dossier becomes the template for regulatory approval in other Latam markets, making it the regional sleep DTx leader. | Successful technology assessment and pilot with a health authority in a country like Colombia or Mexico. | The Abu Dhabi Department of Health has already completed a formal technology status assessment for SleepUp [Abu Dhabi Department of Health (DoH)], demonstrating the model's exportability to other regulated markets. |
Compounding advantages would begin to reinforce these scenarios. The core flywheel is data-driven personalization. Each new user, especially those using the proprietary EEG headband [SleepUp App - App Store, 2026], generates unique sleep biomarker data. This data refines the platform's AI algorithms for recommendations, theoretically improving clinical outcomes [Perplexity Sonar Pro Brief]. Better outcomes lead to higher user retention and more compelling case studies for institutional buyers, which in turn drive more user volume and richer data. This creates a data moat that generic sleep trackers cannot replicate and builds a reputation as the most effective digital intervention, locking in distribution partners who seek proven results. Early evidence of this integration is the platform's design, which combines monitoring, therapy, and remote consultation into a single flow [Abu Dhabi Department of Health (DoH)].
The size of the win can be framed by looking at comparable digital health platforms in specialized therapeutic areas. For example, the global market for sleep tech devices was valued at $21.1 billion in 2023 [gminsights.com, 2026]. While SleepUp's total addressable market is a segment of this, a successful 'B2B2C Pharmacy Dominance' scenario in Brazil alone could support a company valued in the hundreds of millions of dollars. A more direct comparison might be to other venture-backed digital therapeutics companies that have achieved unicorn status by securing reimbursement pathways in single large markets, such as Pear Therapeutics (focused on SUD and insomnia in the US) prior to its challenges. If SleepUp captures a leading share of the digital sleep therapy channel in Brazil and demonstrates exportable regulatory success, a valuation exceeding $500 million is a plausible outcome for that specific scenario, not a forecast.
Data Accuracy: YELLOW -- The core regulatory claim is well-sourced; growth scenarios are extrapolations based on cited commercial positioning and one international assessment. Market size data is from a third-party report.
Sources
PUBLIC
[Digital Therapeutics Alliance] SleepUp | https://dtxalliance.org/members/sleepup/
[Perplexity Sonar Pro Brief] What SleepUp does | https://www.perplexity.ai/
[Health Podcast Network] Sleep and Digital Health in Brazil (Renata Redondo Bonaldi) | https://healthpodcastnetwork.com/episodes/faces-of-digital-health/sleep-and-digital-health-in-brazil-renata-redondo-bonaldi/
[Pequenas Empresas Grandes Negócios, Jul 2025] Negócio dos sonhos: startup que trata a insônia ganha aporte de R$ 2 mi | https://exame.com/tecnologia/negocio-dos-sonhos-startup-que-trata-a-insonia-recebe-aporte-de-2-milhoes/
[Crunchbase] SleepUp - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/sleepup
[Pequenas Empresas Grandes Negócios, Nov 2021] Esta startup quer melhorar a vida de quem sofre de insônia | https://revistapegn.globo.com/Startups/noticia/2021/11/esta-startup-quer-melhorar-vida-de-quem-sofre-de-insonia.html
[Canaltech, Nov 2021] Startup de terapias para insônia SleepUp recebe aporte de R$ 2 milhões | https://canaltech.com.br/startup/startup-de-terapias-para-insonia-sleepup-recebe-aporte-de-r-2-milhoes-201122/
[SleepUp App - App Store, 2026] SleepUp: Sleep better | https://play.google.com/store/apps/details?id=com.sleepup.app
[gminsights.com, 2026] Global Sleep Tech Devices Market Report | https://www.gminsights.com/
[businessresearchinsights.com, 2026] Global Sleeping Pod Market Report | https://www.businessresearchinsights.com/
[Abu Dhabi Department of Health (DoH)] SleepUp - Software as Medical Device | https://www.doh.gov.ae/-/media/Feature/Research/Technology-status/SleepUp.ashx
Articles about SleepUp
- SleepUp's ANVISA-Approved Headband Aims to Treat Insomnia at Scale — The Brazilian digital therapeutic startup has secured over $2 million to combine a Class II medical device app with a proprietary EEG wearable.